From Seekingalpha · Terry Chrisomalis · · 50s
Design Therapeutics DT-216P2 Registrational Update
Design Therapeutics plans registrational filing for DT-216P2 in Q4 2026 with 12-week results expected Q1 2027.
In brief
Design Therapeutics plans registrational filing for DT-216P2 in Q4 2026 with 12-week results expected Q1 2027. Design Therapeutics is holding its lead candidate DT-216P2 for Friedreich Ataxia with a registrational update planned for Q4 2026 and 12-week results in Q1 2027. Originally reported by Seekingalpha.
Investment Rating
Terry Chrisomalis initiates coverage of Design Therapeutics with a hold rating.
“I'm initiating coverage of Design Therapeutics ( DSGN ) with a "Hold" rating”
Lead Candidate Target
Design Therapeutics' lead candidate DT-216P2 targets the root cause of Friedreich Ataxia.
“Design Therapeutics is initiated with a "Hold" rating as its lead candidate, DT-216P2 targets the root cause of Friedreich Ataxia [FA]”
Phase 1/2 Results
The company's 4-week phase 1/2 RESTORE-FA data showed strong biomarker and clinical improvements.
“The company's 4-week phase 1/2 RESTORE-FA data showed strong biomarker and clinical improvements”
Upcoming Catalysts
Confirmation of 12-week results for DT-216P2 FA expected in Q1 2027 with registrational update in Q4 2026.
“Upcoming catalysts include a registrational update in q4 2026 for dt-216p2 fa and early-stage readouts for dm1 and fecd programs in 2027”
Cash Position
Design Therapeutics maintains over $200M in cash supporting operations for 12+ months.
“The company maintains over $200M in cash, supporting operations for 12+ months”
The essence
Design Therapeutics is holding its lead candidate DT-216P2 for Friedreich Ataxia with a registrational update planned for Q4 2026 and 12-week results in Q1 2027.
